A corporate venture fund of a pharmaceutical company has their main office in the US. With its inaugural fund, the firm seeks to invest in technologies that are complementary to the parent pharma company’s R&D activities. The firm seeks to invest $5-7M as initial investment, and can invest up to $20M over the company’s lifecycle. The firm will focus on investing in companies based in the US, Western Europe, and Japan.
The firm focuses on investing in therapeutics, platform technologies, and digital technologies. In therapeutics, the firm has a strong interest in cell/gene therapy, protein degraders, and covalent binders, as well as platform technologies including any platforms that can find or develop drugs across multiple therapeutic areas. Within digital technologies, the firm primarily seeks applications that help with target identification and drug design, accelerating drug discovery and development. The firm is not seeking clinical and patient-centric investments, and does not invest in medical devices or diagnostics. In terms of stage of development, the firm focuses on pre-clinical and early clinical stage opportunities.
The firm does not have specific company or management team requirements. The firm does not lead investments and does not require board representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment